#1 Dividend ETF Yielding Over 10%

This Dividend is Almost 10%

Sponsored

If you're looking for a great income stock… I suggest you watch this. It details a company that has gone from $8 million in profits to $188 million over the last two years. And as a result… the dividend is up 7-fold! It now pays almost 10%. But beyond that… Wall Street analysts are now projecting the $30 stock will jump to $280! Get the details on this amazing income stock right here.

---

JEPI, or the JPMorgan Equity Premium Income ETF, is an exchange-traded dividend-focused fund managed by JPMorgan Asset Management.

It’s currently paying a 10.4% dividend yield and should be on the radar of all investors looking to generate income in the current wavering market conditions we find ourselves in today.

Here's a general overview of JEPI:

1. Objective: JEPI aims to provide investors with consistent income through option writing strategies while also offering the potential for capital appreciation. Essentially, it seeks to generate income primarily through the sale of call options on U.S. equities and, to a lesser extent, from dividends and capital appreciation.
2. Strategy: The fund typically invests in a diversified portfolio of large-cap U.S. equities. Alongside this, it employs a covered call writing strategy. A covered call is an options strategy where an investor holds a long position in an asset and sells or “writes” call options on that same asset to generate additional income.
3. Distribution: One of the notable features of JEPI is its monthly distribution, which can be attractive to income-seeking investors. The fund aims to provide a higher yield than many traditional equity investments.
4. Use Cases: JEPI can be used by investors who are looking for equity exposure with an enhanced income component. It can be especially appealing to those in or nearing retirement who want to generate regular income from their investments.
5. Performance and Risks: Like all investments, JEPI has its risks and rewards. The performance and risk profile can vary based on market conditions, the success of the option writing strategy, and the performance of the underlying equities in the portfolio.

JEPI stands out as a unique offering in the realm of equities. The ETF’s top 10 holdings include: 

With a current yield of 10.4%, it offers an attractive proposition for income-focused investors, especially when compared to other investment vehicles.

Here’s why:

1. Yield Comparison: JEPI's yield significantly outpaces the S&P 500's dividend yield of approximately 1.5-1.6%. Even when compared to other income-focused ETFs, such as the popular Schwab U.S. Dividend Equity ETF (SCHD), JEPI emerges superior. The U.S. 10-year treasury yield, a benchmark for risk-free returns, currently trades at around 4.25%. JEPI's yield of 10.4% is more than double this rate, showcasing its superior income-generating capability.

2. Defensive Asset Allocation: JEPI's defensive stance is evident in its asset allocation strategy. The fund's 1-year Beta stands at 0.64 compared to the S&P 500's 1x Beta. Furthermore, JEPI's 1-year return standard deviation is 13.3%, significantly lower than the S&P 500's 19%. This defensive posture is complemented by a higher earnings growth rate of 10.5% for the trailing twelve months, compared to the S&P 500's 9.9%.

3. Volatility as an Income Generator: One of JEPI's unique strategies is its use of selling volatility through options to generate income. This strategy allows JEPI to benefit from market volatility. The higher the market volatility, the greater the premium JEPI can collect from writing call options. Given the recent uptick in the VIX and the net “Short Gamma” positioning of option dealers and traders for the first time in 2023, JEPI stands to benefit.

4. Diversified Asset Allocation: JEPI's asset allocation is well-diversified across sectors. Approximately 13% is invested in Information Technology, 12.9% in Financials, 12.1% in Health Care, 11.5% in Industrials, and 11.2% in Consumer Staples. This diversification ensures that no single sector or stock can significantly impact the fund's performance.

5. Risks: While JEPI offers a compelling value proposition, it's essential to understand the associated risks. Being an equities fund, JEPI is susceptible to stock price fluctuations. Additionally, its strategy of selling call options can limit its upside during bullish market phases.

Conclusion: Considering the current macro-environment and the potential for increased volatility in the remainder of 2023, JEPI's low-beta and short-duration investment strategy is poised to thrive. With an expected annual income yield of 9-11% and net expenses as low as 0.35% per year, JEPI offers a compelling value proposition for income-focused investors. Based on the above factors and its performance relative to other investment vehicles, JEPI is rated a “Strong Buy”.

---

The Perfect Stock Under $10

Sponsored

If you're looking for a great AI stock under $10… you need to watch this right away.

What the company is doing is pretty incredible. It could end up saving billions of lives… and billions of dollars.

In short, the company is the creator of the first AI-designed drug to enter clinical trials.

And this is a huge deal.

Normally, bringing a new drug to market takes an average of 10 years and between $2.5 and $12 billion.

However, new AI technology has the potential to make the process up to 1000 times faster.

The Wall Street Journal reports that “the time required for the early stages of drug discovery could shrink from years to months.”

Not only that, it has the potential to develop “never-before-seen molecules that could treat diseases like pancreatic cancer or ALS.”

In short, this is groundbreaking stuff.

And this #1 AI company is at the forefront of all of it.

The biggest pharmaceutical companies in the world are lining up to work with them.
For example…

• Merck is collaborating with them on three projects that could generate up to $674 million in revenue.
• French pharma giant Sanofi agreed to pay the company up to $5.2 billion to develop 15 new drugs.
• Bristol Meyers Squibb signed a $1.2 billion partnership with the company.

And yet… the company I'm talking about is valued at just over $500 million today. And it trades for less than $10.

In other words, these deals have the potential to drive the stock many times higher in the months and years ahead.

So again, if you're looking for a great AI stock to own, you need to watch this presentation right away.

P.S. The best way to play this AI stock involves an investment strategy used by a Kansas welder to become one of the wealthiest people in the world.

See his incredible investment approach here.